The guest, Christian Angermayer, discusses his investment approach that spans across psychedelics, AI, and longevity. The conversation highlights recent news in the field, such as the approval of psychedelics for limited settings in Oregon, and explores the interconnectedness of these areas. The chapter provides insight into Christian's unique perspective on life, investing, and his vision for the future.
The Sunday Times' tech correspondent Danny Fortson brings on Christian Angermayer, founder of Apeiron Investments, to talk about psychedelics in Oregon (4:15), the spiritual experience of a “trip” (11:30), progressing toward the first FDA approval (15:30), how this will be introduced into the market (21:10), why having a qualified guide/therapist is critical (25:30), gaining societal acceptance (30:20), why he funded the longevity XPrize (34:20), the new approach to ageing (41:00), why we are on the cusp of a breakthrough in life span (42:30), the Ozempic effect (49:00, thriving in a toxic society (56:20), and how AI dovetails with psychedelics and longevity (1:01:50).
Hosted on Acast. See acast.com/privacy for more information.